Douglas Blayney
Director/Miembro de la Junta en ARTELO BIOSCIENCES, INC. .
Fortuna: 1 118 $ al 30/04/2024
Perfil
Douglas W.
Blayney is the founder of Asco Quality Symposium.
He currently holds the position of Independent Director at Artelo Biosciences, Inc. since 2017 and is a Professor at Stanford University since 2010.
Previously, he served as the Medical Director & Professor at the University of Michigan Comprehensive Cancer Center from 1999 to 2003, the Medical Director at Stanford Cancer Institute from 2010 to 2015, and the President of the American Society of Clinical Oncology, Inc. from 2009 to 2010.
He completed his undergraduate education at Stanford University and the University of California.
Participaciones conocidas en empresas públicas
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
ARTELO BIOSCIENCES INC
0.03% | 22/03/2024 | 834 ( 0.03% ) | 1 118 $ | 30/04/2024 |
Cargos activos de Douglas Blayney
| Empresas | Cargo | Inicio |
|---|---|---|
| ARTELO BIOSCIENCES, INC. | Director/Miembro de la Junta | 31/07/2017 |
| Stanford University | Corporate Officer/Principal | 01/07/2010 |
Antiguos cargos conocidos de Douglas Blayney.
| Empresas | Cargo | Fin |
|---|---|---|
| Stanford Cancer Institute | Corporate Officer/Principal | 01/07/2015 |
American Society of Clinical Oncology, Inc.
 American Society of Clinical Oncology, Inc. Medical/Nursing ServicesHealth Services The American Society of Clinical Oncology is a non-profit organization founded in 1964 with the overarching goals of improving cancer care and prevention. More than 27,000 oncology practitioners belong to ASCO, representing all oncology disciplines and subspecialties. Members include physicians and health-care professionals in all levels of the practice of oncology. American Society of Clinical Oncology is the world’s leading professional organization representing physicians who treat people with cancer. ASCO’s members set the standard for patient care worldwide and lead the way in carrying out clinical research aimed at improving the prevention, diagnosis, and treatment of cancer. ASCO's efforts are also directed toward advocating for policies that provide access to high-quality care for all patients with cancer and at supporting the increased funding for clinical and translational research. | Presidente | 01/07/2010 |
| University of Michigan Comprehensive Cancer Center | Director Técnico/Científico/I+D | 01/06/2003 |
| Asco Quality Symposium | Fundador | - |
Formación de Douglas Blayney.
| Stanford University | Undergraduate Degree |
| University of California | Undergraduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| ARTELO BIOSCIENCES, INC. | Health Technology |
| Empresas privadas | 3 |
|---|---|
American Society of Clinical Oncology, Inc.
American Society of Clinical Oncology, Inc. Medical/Nursing ServicesHealth Services The American Society of Clinical Oncology is a non-profit organization founded in 1964 with the overarching goals of improving cancer care and prevention. More than 27,000 oncology practitioners belong to ASCO, representing all oncology disciplines and subspecialties. Members include physicians and health-care professionals in all levels of the practice of oncology. American Society of Clinical Oncology is the world’s leading professional organization representing physicians who treat people with cancer. ASCO’s members set the standard for patient care worldwide and lead the way in carrying out clinical research aimed at improving the prevention, diagnosis, and treatment of cancer. ASCO's efforts are also directed toward advocating for policies that provide access to high-quality care for all patients with cancer and at supporting the increased funding for clinical and translational research. | Health Services |
| Stanford Cancer Institute | |
| Asco Quality Symposium |
- Bolsa de valores
- Insiders
- Douglas Blayney
